[Frontiers in Bioscience 18, 447-453, January 1, 2013]

CD133+ cancer stem cells in lung cancer

Shuang Wang1, Zhen Ye Xu1, Li Fang Wang1, Wan Su1

1Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. CD133+ cancer stem cells in lung cancer
4. CD133+ cancer stem cells in maintenance of lung cancer
5. CD133+ cancer stem cells in the metastasis of lung cancer
6. CD133+ cancer stem cells in therapy of lung cancer
7. Conclusion
8. References

1. ABSTRACT

Lung cancer is the most preventable cancer worldwide but has a poor prognosis. Recent advances in the study of lung cancer stem cell (CSC) populations has led to a growing recognition of the central importance of cells with stem cell-like properties in lung tumorigenesis. High number of CD133+ cells is associated with the maintenance, metastasis and drug-resistance of lung cancer. CD133 serves as a stemness biomarker for CD133+ CSCs, which have been found in lung cancer tissues. This article reviews the major studies supporting the existence and importance of CD133+ CSCs in the maintenance, metastasis and drug resistance of lung cancer. Continued research in the field of CD133+ CSCs biology is vital, as ongoing efforts promise to yield new prognostic and therapeutic targets.